CASI - CASIファ―マシュ―ティカルズ （CASI Pharmaceuticals Inc.）

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 CASI Pharmaceuticals The Trade: CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) Director James Huang bought a total of 44,527 shares at an average price of $3.75. To … Full story available on Benzinga.com

In the last trading session, 1.37 million CASI Pharmaceuticals Inc. (NASDAQ:CASI) shares changed hands as the company’s beta touched 0.66. With the company’s per share price at $3.24 changed hands at -$0.78 or -19.40% during last session, the market valuation stood at $49.44M. CASI’s last price was a discount, traded about -437.04% off its 52-week … CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Could Make A -980.25% Loss Read More »

CASI Pharmaceuticals, Inc. (NASDAQ:NASDAQ:CASI) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief…

In last trading session, CASI Pharmaceuticals Inc. (NASDAQ:CASI) saw 5.14 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $3.90 trading at $0.89 or 29.57% at ring of the bell on the day assigns it a market valuation of $52.42M. That closing price of CASI’s stock is … CASI Pharmaceuticals Inc. (NASDAQ:CASI) Share Price Recovers 42.56% From Its Lows, But Can It Maintain Its Rise? Read More »

CASI Pharmaceuticals (NASDAQ: CASI ) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings CASI Pharmaceuticals beat estimated earnings by 12.5%, reporting an EPS of $-0.56 versus … Full story available on Benzinga.com

In a challenging market environment, positive insider moves help shore up investor sentiment in a stock. This is exactly the case for biopharmaceutical company CASI Pharmaceuticals, Inc. (CASI), whose CEO just bought a sizable chunk of this penny stock. CASI is focused on progressing its hematology-oncology therapeutic portfolio and aims to be a leader in the Greater China market. Its shares have dropped nearly 65% so far in 2022, and the company had to undertake a 1-for-10 reverse stock split on June 1 to remain compliant with NASDAQ’s minimum bid price requirement. As a result of this maneuver, the company now has about 13.

CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it''s not due to any positive news from the company.

Shares of CASI Pharmaceuticals Inc. are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big gain for the Maryland-based biopharmaceutical company''s stock, closed Wednesday at a pre-split price of 40.63 cents, meaning a 1-for-10 reverse split would adjust the price to $4.063. The stock is currently trading 15.6% below that split-adjusted price. On a pre-split basis, the stock has closed below $1 since Nov. 16, 2021. Through Wednesday, the stock had plunged 94.9% year to date, while the iShares Biotechnology ETF has dropped 24.4% and the S&P 500 has lost 14.0%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Gainers Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) shares jumped 63.9% to $3.9990 after the company announced the USPTO issued a patent to the company titled "Synthetic Chimeric Poxviruses." After the market closed on Tuesday, Tonix also announced a $12.5 million share repurchase program. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) gained 58% to $2.32. Helius Medical Technologies announced the launch of patient therapy access program for Portable Neuromodulation Stimulator. vTv Therapeutics Inc. (NASDAQ: VTVT ) rose 39% to $0.7701 after the company announced entry into agreements that include a $25 million investment by G42 Investments. View, Inc. (NASDAQ: VIEW ) jumped 28% to $1.6250 as the company reported a rise in FY21 sales. Spark Networks SE (NASDAQ: LOV ) gained 27% to $2.68 after the company announced initiation of exploration of strategic alternatives. CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) jumped 26.3% to $0.4350. Casi Pharmaceuticals recently announced a 1-for-10 reverse stock split effective June 1.

Shares of microcap CASI Pharmaceuticals (CASI) are up 42% in premarket trading ahead of a 1-for-10 reverse stock split that becomes effective at 5p ET.

CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it''s not due to any positive news from the company.

Shares of CASI Pharmaceuticals Inc. are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big gain for the Maryland-based biopharmaceutical company''s stock, closed Wednesday at a pre-split price of 40.63 cents, meaning a 1-for-10 reverse split would adjust the price to $4.063. The stock is currently trading 15.6% below that split-adjusted price. On a pre-split basis, the stock has closed below $1 since Nov. 16, 2021. Through Wednesday, the stock had plunged 94.9% year to date, while the iShares Biotechnology ETF has dropped 24.4% and the S&P 500 has lost 14.0%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Gainers Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) shares jumped 63.9% to $3.9990 after the company announced the USPTO issued a patent to the company titled "Synthetic Chimeric Poxviruses." After the market closed on Tuesday, Tonix also announced a $12.5 million share repurchase program. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) gained 58% to $2.32. Helius Medical Technologies announced the launch of patient therapy access program for Portable Neuromodulation Stimulator. vTv Therapeutics Inc. (NASDAQ: VTVT ) rose 39% to $0.7701 after the company announced entry into agreements that include a $25 million investment by G42 Investments. View, Inc. (NASDAQ: VIEW ) jumped 28% to $1.6250 as the company reported a rise in FY21 sales. Spark Networks SE (NASDAQ: LOV ) gained 27% to $2.68 after the company announced initiation of exploration of strategic alternatives. CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) jumped 26.3% to $0.4350. Casi Pharmaceuticals recently announced a 1-for-10 reverse stock split effective June 1.

Shares of microcap CASI Pharmaceuticals (CASI) are up 42% in premarket trading ahead of a 1-for-10 reverse stock split that becomes effective at 5p ET.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)’s traded shares stood at 2.31 million during the last session, with the company’s beta value hitting 0.70. At the close of trading, the stock’s price was $0.52, to imply an increase of 11.56% or $0.05 in intraday trading. The CASI share’s 52-week high remains $1.77, putting it -240.38% down since that … Now Is The Time To Build A Position In CASI Pharmaceuticals Inc. (NASDAQ:CASI) Read More »